Topic
Semiconductor Research
Research across global markets indicates a robust environment for technology-related sectors, driven largely by Nasdaq outperformance and the ongoing integration of AI. The transition of biotechnology toward a scalable industry relies heavily on AI-driven drug discovery, a trend that underscores the increasing importance of high-performance computing infrastructure. Tactical regional themes, particularly in Asian technology, are highlighted as key opportunities for satellite portfolios seeking growth. Furthermore, the global tech economy’s strength is reflected in institutional hedging shifts and record equity highs, despite market caution regarding the exact pace of AI monetization. Recent technical moves, including a 25-year record outperformance in software relative to the S&P 500, suggest a period of high factor volatility and concentrated demand in tech-adjacent growth sectors. As markets navigate these geopolitical and technical shifts, analysts recommend enhancing portfolio resilience through exposure to resilient global markets like Japan and diversifying into alternative assets.
4177 reports available
All reports
Page 164 of 175
BTG Pactual 1Q26 First Take
Goldman Sachs · May 11, 2026
Maintain a Diversified Portfolio Amid Geopolitical Volatility
UBS · May 11, 2026
Global Shipyard Logbook May
Goldman Sachs · May 11, 2026
Americas Healthcare Biotechnology 1Q26 Model Updates
Goldman Sachs · May 11, 2026
Market Focus Shift from Buybacks to Capex
The Market Ear · May 11, 2026
1Q26 Takeaways: Slight Core Beat with Stronger Top Line Across the Board
Goldman Sachs · May 11, 2026
FinecoBank SpA: Management Meeting Takeaways
Goldman Sachs · May 11, 2026
Australian Morning Focus
ANZ · May 11, 2026
Fox Corp F3Q26 Review EBITDA Beat
Goldman Sachs · May 11, 2026
China Restaurants Monthly Tracker
Goldman Sachs · May 11, 2026
Cheniere Energy 1Q26 Recap
Goldman Sachs · May 11, 2026
Clariant Revising Estimates Post 1Q26
Goldman Sachs · May 11, 2026
Deep Dive Into Anduril's Lattice Software Post Leadership Meetings
Goldman Sachs · May 11, 2026
Apogee Therapeutics Analysis: Zumilokibart in Atopic Dermatitis
Goldman Sachs · May 11, 2026
Updating Estimates Post Q1 2026
Goldman Sachs · May 11, 2026
Bubble Study
The Market Ear · May 11, 2026
Evaluating Execution Risk for Avexitide Phase 3 Readout in Post-Bariatric Hypoglycemia
Goldman Sachs · May 11, 2026
Chasing Momentum Into the Void
The Market Ear · May 11, 2026
Deutsche Bank Updating Estimates Post Q1 2026
Goldman Sachs · May 11, 2026
China's Industrial Policy: Lessons and Realities
Natixis Corporate and Investment Banking · May 11, 2026
Ever Higher
Ratios (Natixis / Groupe BPCE) · May 11, 2026
Softbank Corp Upside Potential and New Medium Term Plan
Goldman Sachs · May 11, 2026
Shift Up Corp 1Q26 Review
Goldman Sachs · May 11, 2026
Global Chemicals: Middle East Disruption Around the World - Part II
Goldman Sachs · May 11, 2026